Профилактика и лечение сердечно-сосудистых заболеваний природными антиоксидантами

Обложка

Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Многочисленные эпидемиологические, клинические и терапевтические исследования показали, что природные антиоксиданты можно эффективно использовать для профилактики и лечения сердечно-сосудистых заболеваний, как в чистом виде, так и в составе пищевых продуктов. Сведения о применении антиоксидантов приведены в настоящем кратком обзоре. В качестве подтверждения представлена обширная, хорошо подобранная библиография (более 100 ссылок). Каждое утверждение обосновано соответствующими научными исследованиями.

Полный текст

Доступ закрыт

Об авторах

Л. И. Кедринская

Лечебно-диагностический центр «Профмедпомощь»

Email: yashin@scietegra.com

к. м. н.

Россия

А. Я. Яшин

ООО «Институт аналитической токсикологии»

Автор, ответственный за переписку.
Email: yashin@scietegra.com

к. х. н.

Россия

Я. И. Яшин

ООО «Интерлаб»

Email: yashin@scietegra.com

д. х. н.

Россия

Список литературы

  1. Tardiff J. C., Bouzussa M. G. Antioxidants and cardiovascular disease. Springer, 2012. 270 p.
  2. Oliva P. B. Antioxidants and stem cells for coronary heart disease. Colorado Heart Research and Education Association, 2014. 632 p.
  3. Bourassa M. G., Tardif J. C. Antioxidants and cardiovascular disease. Springer, 2006. 258 p.
  4. Leuci R., Brunetti L., Poliseno V. et al. Natural compounds for the prevention and treatment of cardiovascular and neurodegenerative disease. Foods. 2021; 10: 29–36.
  5. Mangye H., Becker K., Fuchs D., Gostner J. M. Antioxidants, inflammation and cardiovascular disease. World J. Cardiol. 2014; 6: 62–477.
  6. Zhou D. D., Luo M., Shong A. et al. Antioxidant food components for the prevention and treatment of cardiovascular disease: effects, mechanisms and clinical studies. Oxidative Medicine and Cellular Longevity. 2021; 2021: 1–7.
  7. Luo J., le Cessie S., van Heemset D. et al. Diet-Derived circulating antioxidants and risk of coronary heart disease: A Mendelien randomization study. J. Amer. Coll. Cardiology. 2021; 77: 45–54.
  8. Oguntibeju O. O., Esterhuyse A. J., Truter E. J. Cardiovascular disease and the potential protective role of antioxidants. African. J. Biotechn. 2009: 8: 3107–3117.
  9. Cherubini A., Vigna G. B., Zuliani G. et al. Role of antioxidants in atherosclerosis: epidemiological and clinical update. Current Pharmaceutical Design. 2005; 11: 2017–2022.
  10. Giglio R. V., Patti A. M., Cicero. F.G. et al. Polyphenols-potential use in the prevention and treatment of cardiovascular diseases. Current Pharmaceutical Design. 2018; 24: 239–258.
  11. Moore L. L. Functional foods and cardiovascular disease risk-building the evidence base Current Opinion in Endocrinology. 2011; 18: 332–335.
  12. Barrett E. M., Balterham M. J., Ray S. et al. Whole grain, bran and cereal fibre consumption and CVD-A systematic review. Brit. J. Nutr. 2019; 121: 914–937.
  13. Hu F. B. Plant-based foods and prevention of cardiovascular disease-an overview. Am. J. Clin.Nutr. 2003; 78: 544–551S.
  14. Badimon L., Vilahur G., Padro T. Nutraceuticals and atherosclerosis-human trials. Cardiovasc. Therapeutics. 2010; 28: 202–215.
  15. Hu F. B., Willett W. C. Optimal diets for prevention of coronary heart disease. JAMA. 2002; 288: 2569–2578.
  16. Flight I., Clifton P. Cereal grains and legumes in the prevention of coronary heart disease and stroke-a review of literature. Eur. J. Clin. Nutr. 2006; 60: 1145–1159.
  17. Avci E., Dolapoglu A., Akgun D. E. (Eds) Role of cholesterol as risk factor in cardiovascular disease. – In: «Cholesterol-good, bad and the heart». Intech. Open, 2018. 154 p.
  18. Fuchs F. D., dan Whelton P. K. High blood pressure and cardiovascular disease. Hypertension. 2020; 75: 285–292.
  19. Leon B. M. Diabetes and cardiovascular disease-epidemiology, biological mechanisms, treatment. Recommendation and future research. J. Diabetes. 2015; 6: 1246–1253.
  20. McCully K. S. Homocysteine and vascular disease. Nat. Med. 1996; 2: 386–389.
  21. Austin R. C., Leutz S. R., Werstuck G. H. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004; 11: 556–564.
  22. Cercato C., Fonseca F. A. Cardiovascular risk and obesity. Diabetology and metabolic syndrome. 2019; 11: 1–15.
  23. Monrique-Acevedo C., Chinnakalta B., Podilla J. et al. Obesity and cardiovascular disease in women. Intern. J. Obesity. 2020; 44: 1210–1226.
  24. Cervantes Gracia K., Llanas-Cornejo D., Husi H. CVD and oxidative stress. J. Clin. Med. 2017; 6: 22–26.
  25. Dhalla N. S., Temsah R. M., Netticadem T. Role of oxidative stress in cardiovascular disease. J. Hypertens. 2000; 18: 655–673.
  26. Dubois-Deruy E., Peugnet V., Tarkieh A., Pinet F. Oxidative stress in cardiovascular disease. Antioxidants. 2020; 9: 864–876.
  27. Libby P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012; 32: 45–51.
  28. Loren zatt A.J., Servato M. L. New evidence on the role of inflammation in CVD risk. Curr. Opin. Cardiol. 2019; 34: 418–423.
  29. Gianazza E., Brioschi M., Fernandez A. M. er al. Lipid peroxidation – in atherosclerotic cardiovascular disease. Antioxidants Redox Signaling. 2020; 34: 49–98.
  30. Holvoet P., Collen D. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis. 1998; 137: 33–38.
  31. Carnettion M. R. Physical activity and cardiovascular disease. How much is enough Amer. J. Lifestyle. 2009; 3: 1–11.
  32. Harrison D. G. Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest. 1997; 100: 2153–2157.
  33. Brown A. A., Hu F. B. Dietary modulation of endothelial function-implication for cardiovascular disease. Am. J. Clin. Nutr. 2001; 73: 673–686.
  34. Cai H., Harrison D. G. Endothelial dysfunction in cardiovascular disease. The role of oxidant stress. Circ. Res. 2000; 87: 840–844.
  35. Pratico D. Antioxidants and endothelium protection. Atherosclerosis. 2005; 181: 215–224.
  36. Peto R. Smoking and death: the past 40 years and the next 40. Brit.Med J. 1994; 309: 937–939.
  37. Martinez Torres A., Martinez Gaensly M. Helicobacter pylori – a new cardiovascular risk factor. Rev. Esp. Cardiol. 2002; 55: 652–656.
  38. Refai N., Ridker P. M. High sensitivity C-reactive protein. A novel and promising marker of coronary heart disease. Clinical Chemistry. 2001; 47: 403–411.
  39. Subbiah A. K., Chhabra Y. K., Mahajan S. Cardiovascular disease in patients with chronic kidney disease-a neglected subgroups. Heart Asia. 2016; 8: 56–61.
  40. Sanches-Silva A., Testai L., Navali S. E. et al. Therapeutical potential of polyphenol in cardiovascular disease-Regulation of Mtor signaling pathway. Pharmacol. Res. 2020; 152: 104626.
  41. Bahramsoltani R., Ebrahimi F., Farrai M. H. et al. Dietary polyphenols for atherosclerosis. A comprehensive review and future perspectives. Crit. Rev. Food Sci. Nutr. 2019; 59: 114–132.
  42. Vetrani G., Costabile G., Vitale M., Ciacco R. (Poly)phenols and cardiovascular disease-looking in to move for world. J. Funct. Foods. 2021; 71: 104113.
  43. Hertog M. G., Feskens E. J., Hollman P. C.et al. Dietary antioxidant flavonoids and risk of coronary heart disease. The Zutphen elderly study. Lancet. 1993; 342: 1007–1011.
  44. Hodyson J. M., Croff K. D. Tea flavonoids and cardiovascular health. Mol. Aspects Med. 2010; 31: 495–502.
  45. Cassidy A., Bertoia M., Chinve S. et al. Habitual intake of anthocyanins and flavonones and risk of cardiovascular disease in men. Am. J. Clin. Nutr. 2016; 104: 587–594.
  46. Cassidy A. Berry anthocyanin intake and cardiovascular health. Mol. Aspect Med. 2018; 61: 76–82.
  47. Wang Y., Chung S. J., McCullaugh M.L. et al. Dietary carotenoids are associated with cardiovascular disease risk biomarkers mediated by serum carotenoid concentration. J. Nutr. 2014; 144: 1067–1074.
  48. Osganian S. K., Stampfer M. J., Rimm E. Dietary carotenoids and risk of coronary artery disease in women. Am. J. Clin. Nutr. 2003; 77: 1390–1399.
  49. Peterson J., Dnyer J., Adlerorentz H et al. Dietary lignans-physiology and potential for cardiovascular disease risk reduction. Nutr. Rev. 2010; 68: 571–603.
  50. Pins J. J., Kaur H. A review of the effects of barley beta-glucan on cardiovascular and diabetire risk. Cereal Foods World. 2006; 51: 8–11.
  51. Dabeck W. M., Marra M. V. Dietary quercetin and kampferol-Bioavailability and potential cardiovascular –related bioactivity in humans. Nutrients. 2019; 11: 2283–2293.
  52. Deng Q., Li X. X., Fang Y. et al. Therapeutical potential of quercetin as antiatherosclerotic agent in atherosclerotic cardiovascular disease. A review. Evidence-based complementary and alternative medicine. 2020; 2020: 1–12.
  53. Xia N., Daiber A., Forstemann U., Li H. Antioxidant effects of resveratrol in the cardiovascular system. Brit. J. Pharmacol. 2017; 174: 1633–1646.
  54. Arab L., Steck S. Lycopene and cardiovascular disease. Am. J. Clin. Nutr. 2000; 71: 16915–16935.
  55. Fusselt R. G., Coombes J. S. Astaxanthin. A potential therapeutical agents in cardiovascular disease. Mar. Drugs. 2011; 9: 447–465.
  56. Sadanandou N., Cozene B., Cho J. et al. Melatonin – A potential therapeutic for stroke and stroke-related dementia. Antioxidants. 2020; 9: 672–680.
  57. Henkekens C. H., Eberlain K. A randomized trial of aspirin and beta-carotene among us physicians. Preventive Med. 1985; 14: 165–168.
  58. Martelli A., Testai L., Colletti A., Cicera A. F. G. Coenzyme Q10 clinical application in cardiovascular disease. Antioxidants. 2020; 9: 341–350.
  59. Gutierrez-Mariscal F.M., de la Crus-Ares S., Torres-Pena D. et al. Coenzyme Q10 and cardiovascular disease. Antioxidants. 2021; 10: 906–911.
  60. Tuylor F., Huffman M. D., Macedo A. F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst.Rev. 2013; 1: CD004816.
  61. Moon G. J., Kim S. J., Cho Y. H. et al. Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease. J. Clin. Neurol. 2014; 10: 140–147.
  62. Sesso H. D., Buring J. E., Christen W. G. et al. Vitamin E and C in the prevention cardiovascular disease in men. The physicians health study randomised controlled risk. JAMA. 2008; 300: 2123–2133.
  63. Galak P., Kesse-Guyat E., Czemichow S. et al. Effects of B vitamins and omega-3 fatty acids in cardiovascular disease-a randomised placebo controlled trial. BMJ. 2010; 341: 6273–6279.
  64. Flores-Mateo G., Navas-Acien A., Pastor-Barriceso R. et al. Celenium and coronary heart disease-a meta-analysis. Am. J. Clin. Nutr. 2006; 84: 762–773.
  65. Varshney R., Budoff M. J. Garlic and heart disease. J. Nutr. 2016; 146: 416–421S.
  66. Li L., Sun T., Tian J. et al. Garlic in clinical practice – an evidence – based overview. Crit. Rev. Food Sci. Nutr. 2013; 53: 670–681.
  67. Bitok E., Sabate J. Nuts and cardiovascular disease. Progress in cardiovascular disease. 2018; 61: 33–37.
  68. Penny M. Walnuts decrease risk of cardiovascular disease-a summary of efficacy and biological mechanisms. J. Nutr. 2014; 144: 547–554S.
  69. Alissa E. M., Ferns G. A. Dietary fruits and vegetable and cardiovascular disease risk. Crit. Rev. Food Sci. Nutr. 2017; 57: 1950–1962.
  70. Zhao C. N., Meng X., Li y. et al. Fruits for prevention and treatment of cardiovascular disease. Nutrients. 2017; 9: 598–605.
  71. Tang G. Y., Meng X., Li S. et al. Effects of vegetables on cardiovascular disease and related mechanisms. Nutrients. 2017; 9: 857–864.
  72. Kazemirod H., Kazerani H. R. The anti-arrhythmic effects of pomegranate (Punica granatum) and mainly mediated by nitric oxide. J. Berry Res. 2020; 10: 573–584.
  73. Pour masoumi M., Hadi A. et al. The effect of cranberry on cardiovascular metabolic risk factors. A systematic review and meta-analysis. Clin. Nutr. 2020; 39: 774–788.
  74. Covas M. T., Nyyssonen K., Poulsen H. E. et al. The effect of polyphenols in olive oil on heart diseases risk factors- a randomized trial. Ann. Intern. Med. 2006; 145: 333–341.
  75. Ganesan K., Sukaalingam K., Xu B. Impact on consumption and cooking manners of vegetable oils on cardiovascular disease. A Critical review. Trends Food Sci. Techn. 2018; 71: 132–154.
  76. Prasad K. Flax and cardiovascular health. J. Cardiovasc. Pharmacol. 2009; 54: 369–377.
  77. Miyawani T., Aono H., Toyoda-Ono Y et al. Antihypertensive effects of sesamin in humans. J. Nutr. Sci. Vita. 2009; 55: 87–91.
  78. Frankel E. N., Kanner J., German G. B. et al. Inhibition of oxidation of low-density lipoprotein by phenolic substances in red wine. Lancet. 1993; 341: 454–457.
  79. Fang J., Sureda A., Silva A. S. et al. Trends of tea in cardiovascular health and disease – A critical review. Trends Food Sci. Techn. 2019; 88: 385–396.
  80. Corti R., Rommer A. J., Hollenberg N. K. et al. Cocoa and cardiovascular health. Circulation. 2009; 119: 1433–1441.
  81. Kurlandsky S. B., Stote K. S. Cardioprotective effects of chocolate and almond consumption in healthy women. Nutr. Res. 2006; 26: 509–516.
  82. Andre R., Pacheco R., Bourban M.et al. Brown algae potential as a functional food against hypercholesterolemia-review. Foods. 2021; 10: 237–242.
  83. Mahmound A. M., Hernandez Bautista R. J. et al. Beneficial effects of citrus flavonoids on cardiovascular and metabolic health. Oxid. Med. Cell Longev. 2019; 2019: 5484138.
  84. Hanafi N. T., Saidon N. H. et al. Review- ischemic heart disease and the potential role of fenugreek in cardioprotection. J. Teknology. 2022; 84: 183–197.
  85. Rouhi-Boroujeni H., Heidarian E. et al. Medicinal plants with multiple effects on cardiovascular diseases-a systematic review. Curr. Pharm. Dis. 2017: 23: 999–1015.
  86. King D. E. Dietary fiber, inflammation and cardiovascular disease. Mol. Nutr. Food Res. 2005; 49: 594–600.
  87. Rao A. V. Lycopene, tomates and the prevention of coronary heart disease. Exp. Biol. Med. 2002; 227: 908–913.
  88. Verlongiari A. J., Bush M. Prevention and regression of atherosclerosis by alpha-tocopherol. J. Am. Coll. Nutr. 1992; 11: 131–138.
  89. Luo J., Yang P., dan Song B. L. Mechanisms and regulation of cholesterol homeostasis. Nature Review. Molecular Cell Biology. 2020; 27: 225–245.
  90. Fito M., Guxens M., Corello D. et al. Effect of a traditional Mediterranean diet on lipoprotein oxidation. A randomized controlled trial. Arch. Int. Med. 2007; 167: 1195–1203.
  91. Estruch R., Ros E., Salas-Salvado J. et al. Primary prevention of cardiovascular disease with a Mediterranean diet. New Engl. J. Med. 2013; 368: 1279–1290.
  92. Ford E. S. et al. Explaining the decrease in U.S. death from coronary disease 1980–2000 New ENGL. J. Med. 2007; 356: 2388–2398.
  93. Assmanu G., Gotto A. M. HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004; 109: III8-III14.
  94. Mineo C., Deguchi H., Griffin J. H., Shaul P. H. Endothelial and antithrombotic actions of HDL. Circ. Res. 2006; 98: 1352–1364.
  95. Jamashed H., Sultan F., Igbal R., Gilani A. Dietary almond increase serum HDL cholesterol in coronary artery disease patients in a randomized and controlled trial. J. Nutr. 2015; 145: 2287–2292.
  96. Kontush A. HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovascular Research. 2014; 103: 341–349.
  97. Ben-Aicha S., Badiman I., Vilahur G. Advances in HDL-much more than lipid transporters. Int. J. Mol. Sci. 2020; 21: 732–740.
  98. Trakaki A., Marsche G. Current under stanling of the immunomodulatory activities of high-density lipoproteins. Biomedicines. 2021; 9: 587–593.
  99. Mozaffarian D., Wu. J.H.Y. Omega-3 fatty acids and cardiovascular disease effects on risk factors, molecular pathways and clinical events. J. Am. Coll. Cardiol. 2011; 58: 2047–2067.
  100. Ibiebeli T., Nagle C., Bain C., Webb P. Intake of omega-3 and omega-6 fatty acids and risk of ovarian cancer. Cancer causes control. 2012; 23: 1775–1783.
  101. Wu J. H., Micha R., Imamura F. et al. Omega-3 fatty acids and incident type 2 diabetes, a systematic review and meta-analysis. Brit. J. Nutr. 2012; 107: 214–227.
  102. Elagizi A., Lavie C. J., O`Keefe E. et al. An update on omega-3 polyunsatuated fatty acid and cardiovascular health. Nutrients. 2021; 13: 204–2012.
  103. Shahidi F., Amligaipalan P. Omega-3 polyunsaturated fatty acids and their health benefits. Annu. Rev. Food Sci. Technol. 2018; 9: 345–381.
  104. Cook N. R., Appel L. J., Wholton P. K. Lower levels of sodium intake and reduced cardiovascular risk. Circulation. 2014; 129: 981–989.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Кедринская Л.И., Яшин А.Я., Яшин Я.И., 2023

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах